OmniAb Q2 Revenue Triples Estimates, Full-Year Outlook Raised
OABI sits 85% above its 52-week low of $1.3.
Summary
OmniAb delivered a massive Q2 beat with revenue of $13.4M, nearly triple the $4.69M consensus, driven by milestone payments and new program starts. Net loss narrowed to $5.9M, or $0.05 per share. Management raised full-year revenue guidance to $32M-$36M from $28M-$33M and year-end cash expectations to $37M-$41M, signaling sustained momentum. This follows the 8-K filed after the close, adding analyst reaction and price context. The stock closed at $2.03 on August 5, leaving significant room to run toward the $8.00 median target.
At the time of this announcement, OABI was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.7M. The 52-week trading range was $1.30 to $2.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.